VANCOUVER, British Columbia, Oct. 29, 2024 (GLOBE NEWSWIRE) - Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:
- UBS Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings on November 12 in Rancho Palos Verdes, CA.
- Stifel 2024 Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on November 19 at 4:10 pm Eastern Time (ET) in New York, NY.
- Jefferies London Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings on November 20-21 and a fireside chat on November 20 at 2:30 pm Greenwich Mean Time in London, UK.
- Piper Sandler 36th Annual Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and present on December 3 in New York, NY.
- Citi's 2024 Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a panel discussion titled: ‘Novel Antibody Mechanisms in Oncology’ on December 3 at 3:15 pm ET in Miami, FL.
- 7th Annual Evercore HealthCONx Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on December 4 at 7:55 am ET in Coral Gables, FL.
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been accepted and granted Priority Review. A BLA has also been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S. and China.
Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com
-
Zymeworks Announces Participation in Upcoming Investor ConferencesVANCOUVER, British Columbia, Oct. 29, 2024 (GLOBE NEWSWIRE) - Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diver2024-10-29
-
Cavli Wireless Recognized as a Nasscom Emerge 50 Innovator for 2024Cavli Wireless Recognized as a Nasscom Emerge 50 Innovator for 2024, Championing 'Made in India' Deep Tech Solutions to Drive Global IoT and Wireless2024-10-29
-
天鹅季到来!赏天鹅、泡温泉、游小镇…… 开启那香海秋冬度假模式~天气渐凉,转眼已是深秋,又到了大天鹅归来的季节。今年10月11日,首批的5只越冬大天鹅飞抵荣成,比去年提前了4天,也标志着今年的天鹅季已经正式开启。 2022年,大天鹅首次2024-10-29
-
TE H2, Copenhagen Infrastructure Partners, and A.P. Møller Capital Partner for a Large-Scale ProjectUnder the presidency of His Majesty King Mohammed VI of Morocco and His Excellency Emmanuel Macron, President of the French Republic, the government o2024-10-29
-
The world's first 100% “fiber-to-fiber” biorecycled clothing unveiled by multi-brand consortiumThe world's first 100% “fiber-to-fiber” biorecycled clothing unveiled by multi-brand consortium: CARBIOS, On, Patagonia, PUMA, PVH Corp. and Salomon2024-10-29